Somatic mutation in any of the 5 genes (TP53, EZH2, RUNX1, ASLX1, or ETV6) shown in Bejar et al⁴⁸  to have prognostic significance independent of the International Prognostic Scoring System (IPSS) identifies patients from that same cohort with shorter overall survival than predicted by Revised IPSS (IPSS-R) for the 3 lowest IPSS-R risk groups. One-third of patients in the IPSS-R Intermediate risk group have shorter than predicted overall survival and may better categorized using mutation analysis as having higher risk disease. Modified from Bejar¹²⁷  and used with permission.